NCT04371991

Brief Summary

Kisspeptins are a family of neuropeptides that are critical for the puberty initiation and female fertility. The investigators aimed to investigate in this study kisspeptin levels in early pregnancy, ectopic pregnancy, and early pregnancy loss.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
88

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2019

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 5, 2019

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2019

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 5, 2019

Completed
6 months until next milestone

First Submitted

Initial submission to the registry

April 29, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 1, 2020

Completed
Last Updated

May 5, 2020

Status Verified

May 1, 2020

Enrollment Period

7 months

First QC Date

April 29, 2020

Last Update Submit

May 1, 2020

Conditions

Keywords

kisspeptinectopic pregnancy

Outcome Measures

Primary Outcomes (1)

  • Kisspeptin levels in early pregnancy

    Kisspeptin levels can be used for discrimination between ectopic pregnancy and incomplete miscarriage.

    January 2019-January 2020

Study Arms (4)

Group 1

Ectopic pregnancy

Diagnostic Test: blood test

Group 2

Early viable pregnancy

Diagnostic Test: blood test

Group 3

incomplete miscarriage

Diagnostic Test: blood test

Group 4

Healthy women

Diagnostic Test: blood test

Interventions

blood testDIAGNOSTIC_TEST

blood test (serum samples) for biochemical examination

Group 1Group 2Group 3Group 4

Eligibility Criteria

Age18 Years - 37 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Women were considered for the study if they presented between 5-6 weeks of gestation by last menstrual period. Patients were included if they had either confirmed intrauterine pregnancy (IUP) by ultrasound (n=22) or confirmed miscarriage (SAB) by ultrasound (n=20) or ectopic pregnancy.

You may qualify if:

  • Women aged between 18-37 years presented with between 5-6 weeks of gestation by last menstrual period.

You may not qualify if:

  • Women older than 37 years or younger than 18 years
  • Women with a molar pregnancy, multiple gestations, gestational age past 6 weeks at the time of blood draw, or if pregnancies were assisted conceptions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Gaziosmanpasa Taksim Education and Research Hospital

Istanbul, Turkey (Türkiye)

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Kisspeptin is a family of peptide hormones encoded by the KISS1 gene. Kisspeptin acts centrally via the kisspeptin receptor to stimulate the release of gonadotropin-releasing hormone (GnRH) from the hypothalamus and has a critical role in the initiation of puberty. Kisspeptin was first discovered as an inhibitor of tumor metastasis and, as a result, was previously known as metastatin. Kisspeptin is also found in high levels in first-trimester syncytiotrophoblast cells.

MeSH Terms

Conditions

Pregnancy, Ectopic

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Pregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Study Officials

  • sibel bektas, proffessor

    Gaziosmanpasa Taksim Education and Research Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
6 Months
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal investigator, MD

Study Record Dates

First Submitted

April 29, 2020

First Posted

May 1, 2020

Study Start

January 5, 2019

Primary Completion

August 1, 2019

Study Completion

November 5, 2019

Last Updated

May 5, 2020

Record last verified: 2020-05

Locations